International Flavors & Fragrances Inc. (IFF) slips after deep earning
International Flavors & Fragrances Inc. (IFF) beat EPS and revenue estimates, but shares slipped as investors looked past the headline to softer fourth-quarter profit guidance and a revenue outlook still below the Street’s midpoint. Our deep dive breaks down segment growth, margin trends, and what the updated guidance really signals.
International Flavors & Fragrances (IFF) beat third-quarter expectations with adjusted EPS of $0.83 and revenue of $1.94 billion, but the stock slipped about 3% after hours because guidance disappointed. Management raised the low end of full-year revenue and EBITDA guidance, yet the midpoint still trailed Street estimates and fourth-quarter profitability looks softer, especially in Health & Biosciences.
International Flavors & Fragrances Inc. (IFF) slips on earnings beat.
IFF posted adjusted EPS of $0.83 and revenue of $1.94B, topping estimates of $0.813 and $1.91B. However, shares fell about 3% in after-hours trading as investors focused on a softer fourth-quarter profit outlook and guidance that remained below the Street's revenue midpoint.
Key Takeaways
IFF beat consensus with adjusted EPS of $0.83 versus $0.813 and revenue of $1.94B versus $1.91B.
Scent led the quarter with mid-single-digit growth, while Taste also grew at a mid-single-digit rate. Health & Biosciences delivered low-single-digit growth.
Comparable currency-neutral sales increased 5% year over year, while adjusted operating EBITDA rose 6% to $403M.
IFF raised the low end of full-year 2026 revenue guidance to $7.5B from $7.4B and lifted the low end of adjusted operating EBITDA guidance to $1.55B from $1.53B.
The midpoint of the new revenue range, $7.55B, remained below consensus of about $7.589B. Management also flagged softer fourth-quarter profitability, especially in Health & Biosciences.
Analyst sentiment remains constructive, with 25 Buy ratings, 8 Holds, and 1 Sell rating in the latest consensus. Recent target increases came from Oppenheimer, Barclays, UBS, and Benchmark.
Financial Performance: IFF Beats, but the Mix Matters
The latest IFF earnings report delivered a clean top-line beat. Revenue reached $1.94B, above the $1.91B consensus estimate. Adjusted EPS came in at $0.83, ahead of the $0.813 estimate. The EPS beat was modest, but revenue growth gives the result a stronger operating foundation.
Operationally, IFF reported 5% comparable currency-neutral sales growth. Adjusted operating EBITDA increased 6% to $403M. Cash flow from operations reached $820M for the first nine months, up $288M year over year. Those figures point to better conversion of sales into cash, an important part of the company's turnaround.
Scent was the strongest segment. It posted mid-single-digit sales growth, helped by double-digit growth in Fragrance Ingredients and high-single-digit growth in Consumer Fragrance. Fine Fragrance grew at a low-single-digit rate, despite the impact of the conflict in the Middle East.
Taste also grew at a mid-single-digit rate. Health & Biosciences recorded low-single-digit growth, but its outlook carries more risk. Management expects higher costs and reinvestment to weigh on fourth-quarter profitability in that segment.
The EPS trend shows improvement from the most recent quarter, but also highlights volatility. Recent reported readings moved from $0.80 to $1.25, then $0.82 and $0.83. The latest result therefore confirms stabilization, rather than a straight-line earnings recovery.
The guidance change is positive at the low end. Full-year revenue is now expected at $7.5B to $7.6B, compared with the prior range of $7.4B to $7.6B. Adjusted operating EBITDA guidance moved to $1.55B to $1.60B from $1.53B to $1.60B.
Still, the midpoint of the revenue range remains below the roughly $7.589B consensus view. That gap explains why investors treated the beat with caution. IFF improved the floor, but it did not raise the ceiling.
The company also completed its $500M accelerated share repurchase program. Capital returns and debt reduction remain central to the investment case. IFF has outlined more than $1B of debt reduction and a $2.5B share repurchase authorization connected to its Food Ingredients divestiture.
Market Reaction & Analyst Response
The initial market reaction was negative. IFF fell about 3% in after-hours trading after the results, with another report placing the extended-hours decline at 3.2%. The latest regular-session close stood at $92.18, down 2.59%. Trading volume reached 2,954,278 shares against an average of 1,811,932.
That reaction reflects a familiar earnings tension. The company beat the quarter, yet the forward guide did not fully clear the Street's hurdle. In addition, weaker fourth-quarter profitability gives investors a reason to question how much of the recent improvement will reach the bottom line.
The broader analyst view remains favorable. IFF carries a consensus Buy rating, with 25 Buy ratings, 8 Holds, and 1 Sell rating. The reported consensus price target is $97.47.
Recent target actions also lean positive. Oppenheimer analyst Kristen Owen maintained an Outperform rating and raised the target from $95 to $108. Barclays analyst Lauren Lieberman maintained Overweight and raised the target from $90 to $96. UBS kept a Neutral rating while lifting its target from $84 to $91, and Benchmark maintained Buy while increasing its target from $100 to $105.
The pattern is constructive but not unanimous. Higher targets from several firms support the turnaround case, while UBS's Neutral stance and KeyBanc's Sector Weight initiation show that valuation and execution risks still matter. The market is rewarding progress, but it is not granting IFF unlimited credit.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
CEO Erik Fyrwald framed the quarter as operational progress, while also acknowledging the near-term margin issue.
“A solid third quarter” with improved sales and profitability across divisions. - Erik Fyrwald, CEO, IFF earnings call
Fyrwald also said fourth-quarter profitability would soften, particularly in Health & Biosciences, because of higher costs and reinvestment. That comment matters more than the upbeat headline. IFF is still spending to strengthen the business, so stronger sales do not automatically produce equal earnings growth.
“We are transforming IFF with the divestiture of Food Ingredients.” - Erik Fyrwald, CEO, IFF earnings call
The strategic plan centers on a smaller portfolio built around Taste, Scent, and Health & Biosciences. The Food Ingredients transaction values that business at about $4.3B, while IFF plans to retain a 10% ownership stake. The structure gives IFF access to debt reduction and buybacks while keeping some exposure to the divested operation.
“We are pleased with the quality of profitability in the quarter.” - Michael DeVeau, CFO, IFF earnings call
CFO Michael DeVeau has emphasized profitability quality and cash generation during the company's 2026 earnings commentary. The latest numbers support that focus, with operating cash flow of $820M for the first nine months and the completion of the $500M accelerated repurchase.
“The ultimate impact will depend on stand timing, which is expected to occur in early Q1 of 2027.” - Michael DeVeau, CFO, IFF earnings call
That comment refers to working-capital effects from the Food Ingredients separation. IFF expects transaction-related pressure from factoring changes, inventory builds, and supplier prepayments. These items do not undermine the core cash story, but they can make reported cash flow less smooth during the transition.
Bottom Line
IFF delivered a genuine earnings beat, improved its guidance floor, and showed stronger cash generation. However, the stock slipped because the revenue midpoint remains below consensus and fourth-quarter profitability faces pressure, especially in Health & Biosciences. For investors, the opportunity rests on execution of the portfolio simplification, debt reduction, and margin recovery plan.
+Why did International Flavors & Fragrances (IFF) stock fall after earnings?
IFF shares fell about 3% after hours because investors focused on softer fourth-quarter profit guidance and a full-year revenue midpoint that remained below consensus. The company did beat quarterly EPS and revenue estimates, but the forward outlook was not strong enough to offset those concerns.
+Did IFF beat earnings and revenue estimates this quarter?
Yes. International Flavors & Fragrances reported adjusted EPS of $0.83 versus the $0.813 estimate and revenue of $1.94 billion versus the $1.91 billion consensus. Comparable currency-neutral sales rose 5% year over year and adjusted operating EBITDA increased 6% to $403 million.
+What is IFF's updated full-year 2026 guidance?
IFF raised the low end of its full-year 2026 revenue guidance to $7.5 billion from $7.4 billion, with a new range of $7.5 billion to $7.6 billion. It also lifted the low end of adjusted operating EBITDA guidance to $1.55 billion from $1.53 billion.
+Which IFF business segments performed best in the quarter?
Scent led the quarter with mid-single-digit growth, supported by double-digit growth in Fragrance Ingredients and high-single-digit growth in Consumer Fragrance. Taste also grew at a mid-single-digit rate, while Health & Biosciences posted low-single-digit growth.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on IFF?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
